| Literature DB >> 31192297 |
Ryan Weatherwax1,2, Nigel Harris1, Andrew E Kilding3, Lance Dalleck1,2.
Abstract
This study sought to examine time course changes in maximal oxygen consumption (VO 2 max) confirmed with verification testing following 12 weeks of standardized vs. individualized exercise training. Participants (N=39) were randomly allocated to differing exercise intensity prescription groups: ventilatory threshold (individualized) or % heart rate reserve (standardized). At baseline, 4, 8, and 12 weeks, participants completed maximal exercise testing with a verification protocol to confirm 'true VO 2 max.' VO 2 max in the standardized group changed from 24.3±4.6 ml·kg -1 ·min -1 at baseline to 24.7±4.6, 25.9±4.7, and 26.0±4.2 ml·kg -1 ·min -1 at week 4, 8, and 12, respectively, with a significant difference (p<0.05) in VO 2 max at week 8 and 12 compared to baseline. The individualized group had increases in VO 2 max from online 2 9.5±7.5 ml·kg -1 ·min -1 at baseline to 30.6±8.4, 31.4±8.4, and 32.8±8.6 ml·kg -1 ·min -1 at week 4, 8, and 12, respectively. In the individualized group, there were significant differences (p<0.05) in VO 2 max from baseline to week 8 and 12 and a significant increase in VO 2 max from week 8 to 1 online 2 . Although not statistically significant, our preliminary data demonstrates a more rapid and potent improvement in VO 2 max when exercise intensity is individualized. This is the first investigation to employ use of the verification procedure to confirm 'true VO 2 max' changes following exercise training using ventilatory thresholds.Entities:
Keywords: HRR; cardiorespiratory endurance; exercise training; ventilatory threshold; verification protocol
Year: 2019 PMID: 31192297 PMCID: PMC6559817 DOI: 10.1055/a-0867-9415
Source DB: PubMed Journal: Sports Med Int Open ISSN: 2367-1890
Table 1 Physical and physiological characteristics at baseline, week 4, week 8, and 12 weeks for standardized and individualized groups.
| Parameter | Standardized (n=20; women=16, men=4) | Individualized (n=19; women=14, men=5) | ||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Week 4 | Week 8 | Week 12 | Baseline | Week 4 | Week 8 | Week 12 | |
| Age (yr) | 51.2±12.5 | - | - | - | 44.9±11.4 | - | - | - |
| Height (cm) | 168.3±9.5 | - | - | - | 172.1±7.1 | - | - | - |
| Weight (kg) | 83.9±20.7 | 84.0±20.3 | 83.9±20.4 | 83.8±20.3 | 80.6±16.2 | 80.7±15.8 | 80.2±15.2 | 79.9±15.2 |
| BMI | 29.5±5.5 | 29.5±5.3 | 29.5±5.4 | 29.4±5.3 | 27.1±4.2 | 26.9±4.0 | 26.9±3.8 | 26.8±3.8 |
| Resting HR (b·min −1 ) | 70.0±8.8 | 69.9±11.2 | 68.1±8.4 | 68.2±8.0 | 68.8±9.7 | 72.4±8.7 | 69.3±9.4 | 68.1±11.4 |
| Maximal HR (b·min −1 ) | 165.2±16.1 | 164.5±16.2 | 166.3±16.3 | 164.9±15.1 | 170.1±18.4 | 171.7±16.5 | 170.7±14.7 | 169.2±14.4 |
| VO 2 max (L·min −1 ) | 2.0±0.6 | 2.1±0.6 | 2.2±0.6 †‡ | 2.2±0.6 ‡ | 2.4±0.8 | 2.5±0.8 | 2.5±0.8 ‡ | 2.6±0.8 †‡ |
| % Diff in VO 2 max (GXT and Verification) | –0.2±1.8 | 0.0±1.9 | 0.6±1.7 | –0.4±1.8 | 0.2±1.7 | 0.6±2.1 | 0.7±1.8 | –0.7±1.7 |
| % Δ in Absolute VO 2 max | - | 2.0±6.7 | 6.9±8.4 | 7.5±7.7 | - | 3.9±8.0 | 6.1±6.5 | 10.6±5.3 |
Values are mean±SD. BMI, basal metabolic rate; GXT, graded exercise test; HR, heart rate; Δ, change; VO 2 max, maximal oxygen uptake;
† Significantly different from previous time point; ‡ significantly different from baseline
Table 2 Alterations in dietary intake in response to 12 weeks of standardized or individualized CRF training in sedentary adults.
| Parameter | Baseline | Week 12 |
|---|---|---|
|
| ||
| Calorie intake (kcal) | 1520.3±563.2 | 1518±500.8 |
| Carbohydrate (g) | 160.4±60.5 | 158.8±63.9 |
| Lipid (g) | 61.1±31.2 | 62.8±26.4 |
| Protein (g) | 64.1±16.4 | 63.8±22.0 |
| Carbohydrate (%) | 41.7±6.9 | 40.9±7.8 |
| Lipid (%) | 35.9±9.2 | 37.1±8.4 |
| Protein (%) | 18.2±6.3 | 17.8±5.1 |
|
| ||
| Calorie intake (kcal) | 1539.2±493.0 | 1555.8±403.8 |
| Carbohydrate (g) | 168.2±68.6 | 164.5±57.2 |
| Lipid (g) | 68.6±23.4 | 67.5±13.6 |
| Protein (g) | 73.6±36.6 | 64.8±25.2 |
| Carbohydrate (%) | 43.1±8.2 | 41.9±6.7 |
| Lipid (%) | 40.7±7.9 | 40.6±8.1 |
| Protein (%) | 19.6±10.6 | 16.5±3.8 |
Values are mean±SD
Table 3 Exercise prescription and progression for standardized and individualized exercise prescription based on percentage of heart rate reserve and ventilatory thresholds, respectively.
| Standardized | Individualized | |||||||
|---|---|---|---|---|---|---|---|---|
| Week | Target HR | Actual HR | Target Min | Actual Min | Target HR | Actual HR | Target Min | Actual Min |
| 1 | 108±10 to 113±11 | 113±12 | 27±6 to 32±9 | 32±9 | 105±14 to 115±14 | 114±14 | 26±6 to 31±9 | 31±8 |
| 2 | 108±10 to 113±11 | 113±11 | 41±10 to 48±13 | 46±11 | 105±14 to 115±14 | 114±14 | 39±10 to 47±14 | 44±9 |
| 3 | 108±10 to 113±11 | 114±12 | 54±13 to 64±17 | 51±10 | 105±14 to 115±14 | 114±13 | 52±13 to 63±18 | 54±9 |
| 4 | 118±11 to 123±11 | 120±12 | 45±8 to 49±8 | 47±8 | 122±15 to 136±15 | 131±15 | 38±8 to 48±13 | 42±9 |
| 5 | 124±11 to 128±11 | 126±12 | 42±8 to 47±8 | 45±7 | 122±15 to 136±15 | 134±17 | 38±8 to 48±13 | 43±9 |
| 6 | 124±11 to 128±11 | 127±12 | 42±8 to 47±8 | 45±7 | 122±15 to 136±15 | 135±16 | 38±8 to 48±13 | 44±9 |
| 7 | 124±11 to 128±11 | 127±11 | 48±9 to 53±9 | 49±7 | 122±15 to 136±15 | 133±17 | 41±8 to 52±11 | 49±9 |
| 8 | 124±11 to 128±11 | 127±12 | 52±10 to 58±10 | 53±8 | 125±14 to 139±15 | 134±16 | 45±8 to 57±11 | 50±9 |
| 9 | 129±11 to 134±12 | 131±12 | 48±8 to 53±9 | 51±8 | 144±15 to 154±15 | 149±17 | 37±9 to 42±10 | 40±10 |
| 10 | 129±11 to 134±12 | 132±12 | 48±8 to 53±9 | 50±7 | 144±15 to 154±15 | 148±17 | 37±9 to 42±10 | 40±10 |
| 11 | 129±11 to 134±12 | 133±11 | 53±9 to 59±9 | 53±6 | 144±15 to 154±15 | 148±17 | 41±10 to 47±11 | 44±10 |
| 12 | 129±11 to 134±12 | 133±13 | 53±9 to 59±9 | 53±6 | 144±15 to 154±15 | 147±17 | 41±10 to 47±11 | 45±10 |
Values are mean±SD. HR, heart rate; VT1, first ventilatory threshold; VT2, second ventilatory threshold.
Mean±SD HR values represent the average of all three training days within each week with averages calculated based on the recorded measurements obtained at 1 / 3 and 2 / 3 time points during each exercise session.
Fig. 1Group relative VO 2 max at baseline, week 4, week 8, and week 12 for standardized and individualized exercise prescription. † Significantly different from previous time point; ‡ significantly different from baseline.
Fig. 2Comparison of mean GXT trial VO 2 max and verification trial VO 2 max and individual (39 participants) VO 2 max data represented by the line graphs at baseline a , week 4 b , week 8 c , and week 12 d .
Table 4 Graded maximal exercise test and verification protocol speed, grade, and duration for baseline, week 4, week 8, and week 12 testing.
| Standardized | Individualized | Group | |||||
|---|---|---|---|---|---|---|---|
| Time Point | Parameter | GXT | Verification | GXT | Verification | GXT | Verification |
|
|
| 5.2±0.9 | 5.2±0.9 | 6.1±1.4 | 6.1±1.4 | 5.6±1.3 | 5.7±1.3 |
|
| 10.7±2.7 | 11.4±2.7 | 10.5±2.7 | 11.2±2.6 | 10.6±2.7 | 11.3±2.6 | |
|
| 684.8±127.3 | 148.5±28.3 | 672.6±147.8 | 147.6±38.8 | 678.8±136.0 | 148.1±33.4 | |
|
|
| 5.4±0.8 | 5.5±0.7 | 6.1±1.3 | 6.2±1.3 | 5.7±1.1 | 5.8±1.1 |
|
| 10.0±2.0 | 10.7±1.8 | 12.0±3.3 | 12.7±3.2 | 11.0±2.9 | 11.7±2.7 | |
|
| 654.0±111.7 | 154.5±33.0 | 665.5±137.5 | 145.3±27.9 | 659.6±123.4 | 150.0±30.6 | |
|
|
| 5.5±0.7 | 5.5±0.7 | 6.1±1.5 | 6.2±1.5 | 5.8±1.2 | 5.8±1.2 |
|
| 10.0±1.4 | 10.9±1.3 | 12.1±3.2 | 12.8±3.0 | 11.0±2.6 | 11.8±2.4 | |
|
| 638.3±62.4 | 141.8±32.1 | 675.0±114.0 | 148.4±29.1 | 656.2±91.9 | 145.0±30.5 | |
|
|
| 5.6±0.8 | 5.6±0.8 | 6.6±1.8 | 6.7±1.8 | 6.1±1.4 | 6.1±1.5 |
|
| 10.3±1.4 | 11.2±1.4 | 10.5±3.0 | 11.3±2.8 | 10.4±2.3 | 11.2±2.1 | |
|
| 681.8±81.2 | 143.3±35.6 | 652.9±142.6 | 168.2±31.1 | 667.7±114.6 | 155.4±35.3 | |
Values are mean±SD. GXT, graded exercise test.